[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$qures
Insights #
- $qures creators hit X which is XXX% higher than it's daily average.
- $qures posts created is up XXX% from the previous month.
Engagements: XXXXX #
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXX
1 Week: XXXXX -XX%
1 Month: XXXXX +675%
1-Year High: XXXXX on 2025-06-30
1-Year Low: X on 2025-07-08
| Social Network | X |
|---|---|
| Engagements | XXXXX |
Mentions: X #
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
1-Year High: X on 2025-10-04
1-Year Low: X on 2025-04-27
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $qures in the last XX hours which is up XXX% from X in the previous XX hours
Daily Average: X
1-Year High: X on 2025-10-04
1-Year Low: X on 2025-04-27
Top assets mentioned In the posts about $qures in the last XX hours
uniQure N.V. (QURE) Regeneron Pharmaceuticals Inc (REGN) Regeneron Pharmaceuticals Inc (REGN) Novartis AG (NVS) Ionis Pharmaceuticals, Inc. Common Stock (IONS)
Top topics mentioned In the posts about $qures in the last XX hours
$regns, approved, $rhhbys, $ptcts, $qure, regeneron pharmaceuticals inc, stocks healthcare, $regn, $nvs, $clpt, $ions
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$CLPT fanatics have been screaming about this for years now. The lowest risk gene cell therapy programs you can make are for the CNS"
X Link @AB1001_disciple 2025-10-13T16:45Z XXX followers, 3545 engagements
"It looks like AAV gene therapy is finding its niche: local delivery of relatively low doses (E10-E12 total vg) in tissues as contained as possible. Recent clinical wins by $QURE's AMT-130 (intra-parenchymal Huntington's) and $REGN's DB-OTO (intracochlear inherited deafness) support this trend. These follow prior approved drugs like $RHHBY's Luxturna (subretinal LCA2) and $PTCT's Upstaza (intra-parenchymal AADC deficiency) also delivered locally. $NVS' Zolgensma is a special case -- although delivered systemically at relatively high doses the infant BBB remains permissive allowing efficient"
X Link @GerardCaelles 2025-10-13T16:19Z 1099 followers, 13.7K engagements
"Also worth noting that $QURE's X main competitors WVE-003 (file/review 2029-2030 SNP3 carriers only) Roche/ $IONS Tominerson (2030+) and Novartis/PTC PTC518 (2029-30) are way behind and any new therapies that build on AMT-130 likely launch post-2031 at the earliest"
X Link @johnkmason 2025-10-04T16:46Z XXX followers, 1298 engagements